The DOI matches its Crossref record; 241 of the 244 references it cites were found in a registry or an index.
Neuroinflammation in Alzheimer's disease
Open accessAbstract
Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia, and trigger an innate immune response characterised by release of inflammatory mediators, which contribute to disease progression and severity. Genome-wide analysis suggests that several genes that increase the risk for sporadic Alzheimer's disease encode factors that regulate glial clearance of misfolded proteins and the inflammatory reaction. External factors, including systemic inflammation and obesity, are likely to interfere with immunological processes of the brain and further promote disease progression. Modulation of risk factors and targeting of these immune mechanisms could lead to future therapeutic or preventive strategies for Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“since there is a strong correlation between immune activation and oxidative damage in neurodegenerative disease [42,43,44]”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chronic low-grade inflammation contributes to both the onset and progression of AD and PD through microglial activation and pro-inflammatory cytokine release, accelerating neuronal injury [4].”
From What Are the Key Biological Pathways Through Which Lifestyle Factors Influence Neurodegeneration? (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This aligns with biological evidence highlighting the roles of diet and circadian regulation in modulating neuroinflammation and glymphatic clearance [4,5].”
From What Are the Key Biological Pathways Through Which Lifestyle Factors Influence Neurodegeneration? (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During early stages of AD, microglia contribute to Αβ clearance15”
From Amyloid-β induces lipid droplet-mediated microglial dysfunction via the enzyme DGAT2 in Alzheimer’s disease (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Converging lines of evidence from human genetics, neuroimaging and post-mortem brain tissue studies suggest that microglia are major contributors to molecular and phenotypic changes, including synaptic loss and Aβ clearance, in the AD brain [4].”
From Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, microglia, the brain-resident immunocompetent macrophages, also recognize Aβ oligomers via receptors such as CD36, toll-like receptor 4 (TLR4) and TLR6 and triggering receptor expressed on myeloid cells 2 (TREM2), acquiring specific AD-associated phenotypes [14,15,16].”
From Emerging Role of miR-21-5p in Neuron–Glia Dysregulation and Exosome Transfer Using Multiple Models of Alzheimer’s Disease (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In AD, however, a subset of astrocytes undergoes reactive transformation, adopting inflammatory and metabolically altered states that compromise synaptic support and promote neurotoxicity (Heneka et al., 2015; Nassar et al., 2022).”
From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Heneka et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In AD, these networks become maladaptive, leading to sustained inflammation, impaired synaptic support, defective myelination (Nasrabady et al.; 2018, Zhou et al., 2022), and breakdown of the blood-brain barrier (BBB), ultimately amplifying neurodegeneration (Heneka et al., 2015; Sweeney et al., 2018).”
From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Heneka et al., 2015
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Receptors on microglia can bind Aβ fibrils, driving an inflammatory response similar to the M1 (proinflammatory) phenotype observed outside the central nervous system [84].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“The reactive gliosis, encompassing microgliosis and astrogliosis, are prevalent neuropathological hallmarks observed in the brains of both human AD and mouse models of Aβ amyloidosis8,15,16.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Amyloid-associated gliosis is consistently observed in the brains of AD patients15 and amyloidosis mouse models8,16.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Increasing clinical evidence suggests that neuroinflammation functions as a vital factor in AD pathogenesis (2)”
From Understanding monocyte-driven neuroinflammation in Alzheimer’s disease using human cortical organoid microphysiological systems (2025) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“altered microglial function has been implicated in the progression of AD”
From Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses (2022) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, Aβ may initiate microglial activation, resulting in microglial migration to plaques, phagocytosis, and enzymatic degradation of Aβ [37].”
From Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy (2021) · cites this paper as [37]
The cited source says what the claim attributes to it.
In the citing paper
“Astrocytes become reactive and inflammatory, while microglia transition into chronically activated states that can amplify neuroinflammation (Heneka et al., 2015; Sofroniew and Vinters, 2010).”
From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Heneka et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Microglia, the brain's primary immune cells, play a dual and stage-dependent role in AD, initially contributing to Aβ clearance but transitioning into a chronically reactive, pro-inflammatory state under persistent pathological stress (Hansen et al., 2017; Heneka et al., 2015).”
From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Heneka et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Neuroinflammation is a prominent feature of the neuropathology of Alzheimer’s disease (AD), in addition to β-amyloid (Aβ) plaques, tau-containing neurofibrillary tangles (NFT), and synaptic dysfunction followed by neurodegeneration [1].”
From 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Emerging evidence indicates that neuroinflammation, mediated by activated glial cells, plays a fundamental role in the pathogenesis and neurodegeneration of AD [1].”
From 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“While amyloid-β plaques and TAU tangles have long been recognized as pathological hallmarks of AD, emerging research highlights the critical role of neuroinflammation in disease progression [1, 35–37].”
From microRNA-132 attenuates inflammation in induced pluripotent stem cell-derived microglia from Alzheimer’s disease patients (2026) · cites this paper as [35]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Galectin-3 (Gal-3) is a key protein involved in neuroinflammation and is strongly upregulated in neurodegenerative conditions16.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“Neuroinflammation is a common feature of AD9 and GWAS have associated several immune-related genes with AD including ABCA7, CD33, CLU, CR1, MS4A10, 11 and recently TREM2.12, 13”
From Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer's disease (2015) · cites this paper as [9]
In the citing paper
“Clinical evidence shows that TauO and brain inflammation also appear in the preclinical or prodromal AD stage, many decades prior to the onset of dementia. 100”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [100]
In the citing paper
“Furthermore, since the immune response exists throughout the pathological progress of AD [104, 105], suggesting that it may also participate in and aggravate the disease development.”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [104]
In the citing paper
“Plaques were evident in multiple brain regions by 4mo in male and female 5xFAD mice, concomitant with the stereotypical activation and gliosis of plaque- and non-plaque-associated microglia (PAM and NPAM, respectively; Fig. 1A-C) [52, 53].”
From Microglia facilitate loss of perineuronal nets in the Alzheimer's disease brain (2020) · cites this paper as [52]
In the citing paper
“The neurotoxicity of microglial cells may also be related to their expression of tau, which is triggered by the deposition of Aβ in the brain and is known to be neurotoxic149.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [149]
In the citing paper
“In AD brains reactive microglia has been found colocalized with amyloid plaques. In addition, the reactive astrocytes accumulate around senile plaques next to the activated microglia (Heneka et al., 2015).”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Heneka et al., 2015
In the citing paper
“The sustained exposure to cytokines, chemokines and Aβ, could be responsible for the functional impairment of microglial cells located around Aβ− deposits (Heneka et al., 2015).”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Heneka et al., 2015
In the citing paper
“Microglial senescence can enhance the sensitivity of microglia to inflammatory stimuli; this phenomenon is called “priming” (Heneka et al., 2015).”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Heneka et al., 2015
In the citing paper
“Popular neuroprotective strategies for AD management consist of discovering small molecules with the ability to block these Aβ interactions with intracellular and extracellular targets to avoid caspase activation and the expression of proapoptotic proteins, to reduce the stress kinase signaling cascades, to inhibit tau protein phosphorylation, to counterpoise cholinergic functional loss, and to bo”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [37]
In the citing paper
“The FDA has approved two drugs for mild cognitive impairment (MCI) to early, mild stages of AD after years of failed clinical trials. They are aducanemab, and lecanemab, among which aducanemab received accelerated approval [14, 15].”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [15]
In the citing paper
“Neuroinflammation and oxidative stress (OS) are undoubtedly hallmarks of neurodegeneration, contributing to disease progression.”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [42]
In the citing paper
“These genetic findings are further supported by the common observation of aberrantly activated microglia in pathologically relevant AD brain regions, including within and surrounding Aβ plaques [59, 60].”
From Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau (2021) · cites this paper as [60]
In the citing paper
“Indeed, many of the risk genes associated with AD mediate their effects through microglia, the brain‐resident macrophages (Glass et al, 2010; Heneka et al, 2015; Nott et al, 2019).”
From Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease (2022) · cites this paper as Heneka et al, 2015
In the citing paper
“Neuroinflammation has been identified as a key contributor to the pathobiology of AD [2–4]”
In the citing paper
“and occurs at early disease stages [2, 5–7]”
In the citing paper
“Peripheral inflammation may exacerbate neuroinflammation [2].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
Glutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,188
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175
Richness of human gut microbiome correlates with metabolic markers
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.-M., Kennedy, S., et al. (2013) · Nature · doi:10.1038/nature12506 · Cited by 4,662
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Cited by
Sorted by citations
Items 701–800 of 1,118
Zhang, Y., Che, M., Yuan, J., Yu, Y., Cao, C., Qin, X.-Y., & Cheng, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.21060 · Cited by 98
Microglia responses to interleukin‐6 and type I interferons in neuroinflammatory disease
West, P. K., Viengkhou, B., Campbell, I. L., & Hofer, M. J. (2019) · Glia · doi:10.1002/glia.23634 · Cited by 101
Medrano-Jiménez, E., Jiménez-Ferrer, I., Pedraza‐Escalona, M., Ramírez-Serrano, C. E., Álvarez‐Arellano, L., Cortés‐Mendoza, J., Herrera-Ruiz, M. L., Jiménez‐Ferrer, E., Zamilpa, A., Tortoriello, J., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1515-3 · Cited by 100
De, S., Whiten, D. R., Ruggeri, F. S., Hughes, C. D., Rodrigues, M., Sideris, D. I., Taylor, C. G., Aprile, F. A., Muyldermans, S., Knowles, T. P. J., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0777-4 · Cited by 97
Pan, J., & Wan, J. (2020) · Journal of Immunological Methods · doi:10.1016/j.jim.2020.112834 · Cited by 99
Long, H., Zhou, Z.-W., Cheng, Y., Luo, H., Li, F., Xu, S., & Gao, L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.888989 · Cited by 100
Li, S., Cai, Y., Guan, T., Zhang, Y., Huang, K., Zhang, Z., Cao, W., & Guan, X. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2374608 · Cited by 105
Kuzu, O. F., Granerud, L. J. T., & Saatcioglu, F. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02439-w · Cited by 128
Microglial activation occurs late during preclinical Alzheimer's disease
Streit, W. J., Braak, H., Del Tredici, K., Leyh, J., Lier, J., Khoshbouei, H., Eisenlöffel, C., Müller, W., & Bechmann, I. (2018) · Glia · doi:10.1002/glia.23510 · Cited by 98
Molecular imaging of neuroinflammation in Alzheimer's disease and mild cognitive impairment
Knezevic, D., & Mizrahi, R. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.007 · Cited by 97
An Integrated View on Vascular Dysfunction in Alzheimer’s Disease
Klohs, J. (2019) · Neurodegenerative Diseases · doi:10.1159/000505625 · Cited by 111
Rajasekar, N., Nath, C., Hanif, K., & Shukla, R. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0169-8 · Cited by 94
Chang, E. H., Chavan, S. S., & Pavlov, V. A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00263 · Cited by 98
P‐glycoprotein: a role in the export of amyloid‐β in Alzheimer's disease?
Chai, A. B., Leung, G. K. F., Callaghan, R., & Gelissen, I. C. (2019) · FEBS Journal · doi:10.1111/febs.15148 · Cited by 100
Olvera-Rosales, L. B., Cruz-Guerrero, A. E., Ramírez‐Moreno, E., Lira, A. Q., Contreras‐López, E., Ordaz, J. J., Ovando, A. C., Añorve‐Morga, J., Calderón‐Ramos, Z. G., Arias‐Rico, J., et al. (2021) · Foods · doi:10.3390/foods10061261 · Cited by 108
Rong, Y., Ji, C., Wang, Z., Ge, X., Wang, J., Wu, Y., Tang, P., Jiang, D., Fan, J., Yin, G., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02268-y · Cited by 96
Neuroinflammation, Its Role in Alzheimer's Disease and Therapeutic Strategies
Király, M., Foss, J. F., & Giordano, T. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.109 · Cited by 111
Passive anti-amyloid β immunotherapy in Alzheimer's disease—opportunities and challenges
Heneka, M. T., Morgan, D., & Jessen, F. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01883-x · Cited by 107
Self-citationNeuroinflammation in Lewy body dementia
Surendranathan, A., Rowe, J. B., & O'Brien, J. T. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.10.009 · Cited by 99
Stratoulias, V., Ruiz, R., Kanatani, S., Osman, A. M., Keane, L., Armengol, J. A., Rodríguez-Moreno, A., Murgoci, A.-N., García-Domínguez, I., Alonso-Bellido, I., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01326-3 · Cited by 96
Self-citationAnti-Viral Properties of Amyloid-β Peptides
Bourgade, K., Dupuis, G., Frost, E. H., & Fülöp, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160517 · Cited by 97
Derk, J., MacLean, M., Juranek, J., & Schmidt, A. M. (2018) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000421 · Cited by 96
The emerging roles of protein homeostasis‐governing pathways in Alzheimer's disease
Cheng, J., North, B. J., Zhang, T., Dai, X., Tao, K., Guo, J., & Wei, W. (2018) · Aging Cell · doi:10.1111/acel.12801 · Cited by 102
ER stress activates immunosuppressive network: implications for aging and Alzheimer’s disease
Salminen, A., Kaarniranta, K., & Kauppinen, A. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01904-z · Cited by 99
Tsartsalis, S., Sleven, H., Fancy, N., Wessely, F., Smith, A. M., Willumsen, N., Cheung, T. K. D., Rokicki, M. J., Chau, V., Ifie, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46630-z · Cited by 95
Wróbel-Biedrawa, D., Grabowska, K., Galanty, A., Sobolewska, D., & Podolak, I. (2022) · Life · doi:10.3390/life12040591 · Cited by 95
Corlier, F. W., Hafzalla, G. W., Faskowitz, J., Kuller, L. H., Becker, J. T., López, O. L., Thompson, P. M., & Braskie, M. N. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2017.12.027 · Cited by 103
Wang, X., Li, G., Guo, J., Zhang, Z., Zhang, S., Zhu, Y., Cheng, J., Yu, L., Ji, Y., & Tao, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01393 · Cited by 95
Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing
Fang, J., Pieper, A. A., Nussinov, R., Lee, G., Bekris, L. M., Leverenz, J. B., Cummings, J. L., & Cheng, F. (2020) · Medicinal Research Reviews · doi:10.1002/med.21709 · Cited by 96
Henn, R. E., Noureldein, M. H., Elzinga, S. E., Kim, B., Savelieff, M. G., & Feldman, E. L. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105766 · Cited by 99
Hook, G., Reinheckel, T., Ni, J., Wu, Z., Kindy, M. S., Peters, C., & HOOK, V. Y. H. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000527 · Cited by 98
Exosomes as a potential novel therapeutic tools against neurodegenerative diseases
Jarmalavičiūtė, A., & Pivoriūnas, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.02.002 · Cited by 95
Oeckl, P., Anderl-Straub, S., Von Arnim, C. A. F., Baldeiras, I., Diehl-Schmid, J., Grimmer, T., Halbgebauer, S., Kort, A. M., Lima, M., Marques, T. M., et al. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328547 · Cited by 94
Lutein and Zeaxanthin Influence Brain Function in Older Adults: A Randomized Controlled Trial
Lindbergh, C. A., Renzi-Hammond, L. M., Hammond, B. R., Terry, D. P., Mewborn, C. M., Puente, A. N., & Miller, L. S. (2018) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617717000534 · Cited by 94
Blood–brain barrier leakage and perivascular inflammation in cerebral amyloid angiopathy
Kozberg, M. G., Yi, I., Freeze, W. M., Auger, C. A., Scherlek, A. A., Greenberg, S. M., & van Veluw, S. J. (2022) · Brain Communications · doi:10.1093/braincomms/fcac245 · Cited by 94
Role of RhoA/ROCK signaling in Alzheimer’s disease
Cai, R., Wang, Y., Huang, Z., Zou, Q., Pu, Y., Yu, C., & Cai, Z. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113481 · Cited by 96
Type-I interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer’s disease
Taylor, J. M., Moore, Z., Minter, M. R., & Crack, P. J. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1745-4 · Cited by 94
Beckers, L., Ory, D., Geric, I., Declercq, L., Koole, M. J. B., Kassiou, M., Bormans, G. M., & Baes, M. I. (2017) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1099-1 · Cited by 105
Extracellular vesicles in neurodegenerative diseases
Croese, T., & Furlan, R. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.006 · Cited by 95
Madhu, L. N., Attaluri, S., Kodali, M., Shuai, B., Upadhya, R., Gitaí, D. L. G., & Shetty, A. K. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.06.040 · Cited by 94
Boleti, A. P. D. A., Flores, T. M. D. O., Moreno, S. E., dos Anjos, L. C., Mortari, M. R., & Migliolo, L. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104714 · Cited by 94
Garbuz, D. G., Zatsepina, O. G., & Evgen’ev, M. B. (2021) · Molecular Biology · doi:10.1134/s002689332104004x · Cited by 95
Glaucoma: from pathogenic mechanisms to retinal glial cell response to damage
Fernández‐Albarral, J. A., Ramirez, A. I., de Hoz, R., Matamoros, J. A., Salobrar‐García, E., Elvira‐Hurtado, L., López‐Cuenca, I., Sánchez-Puebla, L., Salazar, J. J., & Ramirez, J. M. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1354569 · Cited by 105
Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies
Mallick, R., Basak, S., Chowdhury, P., Bhowmik, P., Das, R. K., Banerjee, A., Paul, S., Pathak, S., & Duttaroy, A. K. (2025) · Pharmaceuticals · doi:10.3390/ph18010104 · Cited by 108
Porter, V. R., Buxton, W. G., & Avidan, A. Y. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0631-8 · Cited by 94
Inflammasome-mediated innate immunity in Alzheimer’s disease
Venegas, C., & Heneka, M. T. (2019) · The FASEB Journal · doi:10.1096/fj.201900439 · Cited by 93
Self-citationAmyloid‐β impairs the phagocytosis of dystrophic synapses by astrocytes in Alzheimer's disease
Sanchez‐Mico, M. V., Jimenez, S., Gomez‐Arboledas, A., Muñoz‐Castro, C., Romero‐Molina, C., Navarro, V., Sanchez‐Mejias, E., Nuñez‐Diaz, C., Sanchez‐Varo, R., Galea, E., et al. (2021) · Glia · doi:10.1002/glia.23943 · Cited by 93
Savonenko, A. V., Melnikova, T., Wang, Y., Ravert, H. T., Gao, Y., Koppel, J. L., Lee, D., Pletniková, O., Cho, E., Sayyida, N., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129618 · Cited by 97
Han, B., Li, X., & Hao, J. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.002 · Cited by 97
Qi, G., Mi, Y., Fan, R., Li, R., Liu, Z., & Liu, X. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b00133 · Cited by 95
Henriques, J. F., Serra, D., Dinis, T. C. P., & Almeida, L. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228653 · Cited by 95
Lipocalin 2 as a link between ageing, risk factor conditions and age-related brain diseases
Dekens, D. W., Eisel, U. L. M., Gouweleeuw, L., Schoemaker, R. G., Deyn, P. P. D., & Naudé, P. J. W. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101414 · Cited by 93
Augusto‐Oliveira, M., Arrifano, G. D. P., Leal-Nazaré, C. G., Santos-Sacramento, L., Lopes-Araújo, A., Royes, L. F. F., & Lopez, M. E. C. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03492-8 · Cited by 115
Functional Roles of the Interaction of APP and Lipoprotein Receptors
Pohlkamp, T., Wasser, C. R., & Herz, J. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00054 · Cited by 92
Sharma, A., Kazim, S. F., Larson, C. S., Ramakrishnan, A., Gray, J. D., McEwen, B. S., Rosenberg, P. A., Shen, L., & Pereira, A. C. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903566116 · Cited by 92
Dong, Y., Xu, M., Kalueff, A. V., & Song, C. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1462-7 · Cited by 92
Zalpoor, H., Akbari, A., Samei, A., Forghaniesfidvajani, R., Kamali, M., Afzalnia, A., Manshouri, S., Heidari, F., Pornour, M., Khoshmirsafa, M., et al. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00311-1 · Cited by 92
Yang, L., Wu, C., Li, Y., Dong, Y., Wu, C. Y., Lee, R. H., Brann, D. W., Lin, H. W., & Zhang, Q. (2022) · GeroScience · doi:10.1007/s11357-022-00534-2 · Cited by 100
The Influence of Serum Uric Acid on the Brain and Cognitive Dysfunction
Mijailović, N. R., Vesić, K., & Borovčanin, M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.828476 · Cited by 102
Shen, X., Huang, S., Cui, M., Zhao, Q., Guo, Y., Huang, Y., Zhang, W., Ma, Y., Chen, S.-D., Zhang, Y.-R., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad018 · Cited by 99
Neuroinflammation in motor neuron disease
Endo, F., Komine, O., & Yamanaka, K. (2016) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12309 · Cited by 95
Self-citationFörsti, A., Jokelainen, J. J., Ansakorpi, H., Seppänen, A., Majamaa, K., Timonen, M., & Tasanen, K. (2016) · Scientific Reports · doi:10.1038/srep37125 · Cited by 91
Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease
Beggiato, S., Tomasini, M. C., & Ferraro, L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00821 · Cited by 95
Long-Term Dabigatran Treatment Delays Alzheimer’s Disease Pathogenesis in the TgCRND8 Mouse Model
Cortés‐Canteli, M., Kruyer, A., Fernandez‐Nueda, I., Marcos-Díaz, A., Cerón, C., Richards, A. T., Jno-Charles, O. C., Rodríguez, I., Callejas, S., Norris, E. H., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.081 · Cited by 95
Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer's Disease
Griñán‐Ferré, C., Codony, S., Pujol, E., Yang, J., Leiva, R., Escolano, C., Puigoriol‐Illamola, D., Companys‐Alemany, J., Corpas, R., Sanfeliu, C., et al. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00854-1 · Cited by 99
Jung, E. S., Suh, K., Han, J., Kim, H., Kang, H., Choi, W., & Mook‐Jung, I. (2022) · Aging Cell · doi:10.1111/acel.13623 · Cited by 97
Early Changes in Hippocampal Neurogenesis in Transgenic Mouse Models for Alzheimer’s Disease
Unger, M. S., Marschallinger, J., Kaindl, J., Höfling, C., Roßner, S., Heneka, M. T., der Linden, A. V., & Aigner, L. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0018-9 · Cited by 96
Self-citationDaSilva, N. A., Nahar, P. P., Ma, H., Eid, A., Wei, Z., Meschwitz, S. M., Zawia, N. H., Slitt, A. L., & Seeram, N. P. (2017) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1360558 · Cited by 94
Zhang, Z., Li, X., Wang, Z.-H., Song, M., Yu, S. P., Kang, S. S., Liu, X., Zhang, Z., Xie, M., Liu, G., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0286-z · Cited by 91
Microbiota-gut-brain axis and toll-like receptors in Alzheimer’s disease
Lin, C., Zhao, S., Zhu, Y., Fan, Z., Wang, J., Zhang, B., & Chen, Y. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.09.008 · Cited by 94
The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation
Young, A. P., & Denovan‐Wright, E. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.806417 · Cited by 92
Inflammation at the crossroads of COVID-19, cognitive deficits and depression
Silva, N. M. L. E., Barros‐Aragão, F. G. Q., Felice, F. G. D., & Ferreira, S. T. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109023 · Cited by 96
Influences of dopaminergic system dysfunction on late-life depression
Taylor, W. D., Zald, D. H., Felger, J. C., Christman, S., Claassen, D. O., Horga, G., Miller, J. M., Gifford, K., Rogers, B., Szymkowicz, S. M., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01265-0 · Cited by 89
Neuroinflammation in dementia with Lewy bodies: a human post-mortem study
Amin, J., Holmes, C., Dorey, R. B., Tommasino, E., Casal, Y. R., Williams, D. M., Dupuy, C., Nicoll, J. A. R., & Boche, D. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00954-8 · Cited by 89
Self-citationBettcher, B. M., Fitch, R., Wynn, M. J., Lalli, M. A., Elofson, J., Jastrzab, L., Mitic, L., Miller, Z. A., Rabinovici, G. D., Miller, B. L., et al. (2016) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.05.004 · Cited by 89
Adams, J. N., Lockhart, S. N., Li, L., & Jagust, W. J. (2018) · Cerebral Cortex · doi:10.1093/cercor/bhy078 · Cited by 90
Faivre, É., Coelho, J. E., Zornbach, K., Malik, E. M., Baqi, Y., Schneider, M., Cellai, L., Carvalho, K., Sebda, S., Figeac, M., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00235 · Cited by 93
Self-citationSong, Y., Hu, M., Zhang, J., Teng, Z., & Chen, C. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.059 · Cited by 91
Glutaminase in microglia: A novel regulator of neuroinflammation
Ding, L., Xu, X., Li, C., Wang, Y., Xia, X., & Zheng, J. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.11.038 · Cited by 91
Elyahu, Y., & Monsonego, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101231 · Cited by 93
Versace, V., Sebastianelli, L., Ferrazzoli, D., Romanello, R., Ortelli, P., Saltuari, L. L., D’Acunto, A., Porrazzini, F., Ajello, V., Oliviero, A., et al. (2021) · Clinical Neurophysiology · doi:10.1016/j.clinph.2021.03.001 · Cited by 95
Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer's disease
Apátiga-Pérez, R., Soto-Rojas, L. O., Campa-Córdoba, B. B., Luna‐Viramontes, N. I., Cuevas, E., Villanueva‐Fierro, I., Ontiveros‐Torres, M. Á., Bravo-Muñoz, M., Flores-Rodríguez, P., Garcés‐Ramírez, L., et al. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00814-4 · Cited by 92
Investigation of the Molecular Role of Brain-Derived Neurotrophic Factor in Alzheimer’s Disease
Girotra, P., Behl, T., Sehgal, A., Singh, S., & BUNGAU, S. G. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01824-8 · Cited by 92
Revisiting the critical roles of reactive astrocytes in neurodegeneration
Qian, K., Jiang, X., Liu, Z., Zhang, J., Fu, P. F., Su, Y., Brazhe, N. A., Liu, D., & Zhu, L. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02061-8 · Cited by 101
Wong-Guerra, M., Calfío, C., Maccioni, R. B., & Rojo, L. E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1161850 · Cited by 97
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 99
Femminella, G. D., Ninan, S., Atkinson, R., Fan, Z., Brooks, D. J., & Edison, P. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150827 · Cited by 88
Self-citationSpäni, C., Suter, T., Derungs, R., Ferretti, M. T., Welt, T., Wirth, F., Gericke, C., Nitsch, R. M., & Kulic, L. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0251-x · Cited by 88
Manousopoulou, A., Gatherer, M., Smith, C., Nicoll, J. A. R., Woelk, C. H., Johnson, M., Kalaria, R. N., Attems, J., Garbis, S. D., & Carare, R. O. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12342 · Cited by 90
Mishra, S. K., Singh, S., Shukla, S., & Shukla, R. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.11.012 · Cited by 90
Classics in Chemical Neuroscience: Donepezil
Brewster, J. T., Dell’Acqua, S., Thach, D. Q., & Sessler, J. L. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00517 · Cited by 94
Millot, P., San, C., Bennana, E., Porte, B., Vignal, N., Hugon, J., Paquet, C., Hosten, B., & Mouton‐Liger, F. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.10.004 · Cited by 90
Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
Thijssen, E. H., Verberk, I. M. W., Kindermans, J., Abramian, A., Vanbrabant, J., Ball, A. J., Pijnenburg, Y. A. L., Lemstra, A. W., van der Flier, W. M., Stoops, E., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12285 · Cited by 89
Glial Glutamine Homeostasis in Health and Disease
Andersen, J. V., & Schousboe, A. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03771-1 · Cited by 92
Yang, J., Liang, J., Hu, N., He, N., Liu, B., Liu, G., & Qin, Y. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70091 · Cited by 109
Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead
Novak, P., Kontsekova, E., Zilka, N., & Novak, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00798 · Cited by 87
Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease
Hunter, S., & Brayne, C. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.218 · Cited by 94
Aβ propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease
Condello, C., & Stöhr, J. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.03.014 · Cited by 92
Healthy brain aging: Interplay between reactive species, inflammation and energy supply
Garaschuk, O., Semchyshyn, H. M., & Lushchak, V. I. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.02.003 · Cited by 91
Self-citationL-Norvaline Reverses Cognitive Decline and Synaptic Loss in a Murine Model of Alzheimer’s Disease
Polis, B., Srikanth, K. D., Elliott, E., Gil-Henn, H., & Samson, A. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0669-5 · Cited by 79
Metadata
- Authors
- Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., Herrup, K., Frautschy, S. A., Finsen, B., Brown, G. C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Latz, E., Halle, A., Petzold, G. C., Town, T., Morgan, D., Shinohara, M. L., Perry, V. H., Holmes, C., Bazan, N. G., Brooks, D. J., Hunot, S., Joseph, B., Deigendesch, N., Garaschuk, O., Boddeke, E., Dinarello, C. A., Breitner, J. C., Cole, G. M., Golenbock, D. T., & Kummer, M. P.
- Affiliations
- University of Bonn (DE)
- University of California, Riverside (US)
- Case Western Reserve University (US)
- German Center for Neurodegenerative Diseases (DE)
- University of Illinois Chicago (US)
- University of Münster (DE)
- Cleveland Clinic (US)
- Hong Kong University of Science and Technology (HK)
- University of California, Los Angeles (US)
- University of Southern Denmark (DK)
- University of Cambridge (GB)
- Ikerbasque (ES)
- RIKEN (JP)
- Center of Advanced European Studies and Research (DE)
- University of Southern California (US)
- Duke Medical Center (US)
- Southampton General Hospital (GB)
- Southern Health NHS Foundation Trust (GB)
- Louisiana State University (US)
- Hammersmith Hospital (GB)
- Centre National de la Recherche Scientifique (FR)
- Karolinska Institutet (SE)
- Max Planck Institute for Infection Biology (DE)
- University of Tübingen (DE)
- University Medical Center Groningen (NL)
- University of Colorado Denver (US)
- Douglas Mental Health University Institute (CA)
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Heneka, Michael T
- ORCID
- Heneka, Michael T
- Carson, Monica J
- Landreth, Gary E
- Brosseron, Frederic
- Feinstein, Douglas L
- Jacobs, Andreas H
- Ransohoff, Richard M
- Herrup, Karl
- Frautschy, Sally A
- Finsen, Bente
- Brown, Guy C
- Verkhratsky, Alexei
- Yamanaka, Koji
- Latz, Eicke
- Halle, Annett
- Petzold, Gabor C
- Shinohara, Mari L
- Perry, V Hugh
- Holmes, Clive
- Bazan, Nicolas G
- Brooks, David J
- Hunot, Stéphane
- Joseph, Bertrand
- Deigendesch, Nikolaus
- Garaschuk, Olga
- Boddeke, Erik
- Dinarello, Charles A
- Breitner, John C
- Golenbock, Douglas T
- Kummer, Markus P
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 14
- Issue
- 4
- Pages
- 388-405
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC5909703
- OpenAlex
- W2087243986
- Cited by
- 6,226
- References
- 244
- Citations by year
- 2026: 686 · 2025: 708 · 2024: 713 · 2023: 640 · 2022: 665 · 2021: 620 · 2020: 554 · 2019: 506 · 2018: 406 · 2017: 342 · 2016: 259 · 2015: 110
- FWCI
- 29.69
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- HAL (submittedVersion, other-oa)
- Max Planck Digital Library (submittedVersion)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by-nc-nd)
- DZNE Pub (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Funders
- Medical Research Council (MR/L010593/1)
- Japan Society for the Promotion of Science (26293208)
- National Institute on Aging (R21AG053884)
- National Institute of Neurological Disorders and Stroke (R01NS059005, R01NS076794)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, neuroinflammation, innate immunity, microglia, astrocytes, pattern recognition receptors, protein aggregation, misfolded proteins, inflammatory mediators, systemic inflammation, obesity, genetic risk factors, therapeutic target
- MeSH terms
- Alzheimer Disease, Animals, Anti-Inflammatory Agents, Non-Steroidal, Astrocytes, Brain Injuries, Clinical Trials as Topic, Disease Models, Animal, Humans, Immunity, Innate, Immunization, Inflammation, Locus Coeruleus, Obesity, Phagocytosis, Risk Factors, Severity of Illness Index, Biomarkers, Protein Folding, Microglia, Disease Progression, Nootropic Agents, Inflammation Mediators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
